http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2401913-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e55a26d5c1dc868ac485081fbba73fd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H70-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10 |
| filingDate | 2002-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74c7aa9011eb96c1fa57ab982b57dcc4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_129da4a3eb07bf224b8fa81f7b0de019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59a9b5bc8ceb37f43a36ae8f75d5c58d |
| publicationDate | 2004-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2401913-A1 |
| titleOfInvention | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response |
| abstract | A method, apparatus and system for use in treating a patient receiving an antineoplastic drug to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the antineoplastic drug to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the antineoplastic drug's action. Given the effectiveness of the antineoplastic drug's action relative to the surrogate markers, a change in antineoplastic drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the antineoplastic drug dose change on the surrogate markers. |
| priorityDate | 1999-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 216.